With close to 30-40 basic screening tests available, the unit encompasses all the essential parameters typically covered in annual health check-ups
The product will be manufactured at the group's formulation manufacturing facility in Baddi, Himachal Pradesh (India)
Adding 20,000 liters of installed biologics drug substance manufacturing capacity
Dolutegravir Tablets for Oral Suspension (RLD Tivicay PD®) had estimated annual sales of USD 1 million in the U.S. (IQVIA MAT March 2023)
Cyanocobalamin Nasal Spray (RLD Nascobal) had estimated annual sales of USD 69 million in the U.S. (IQVIA MAT Mar 2023)
The identified products for Active Pharmaceutical Ingredients (API) will be developed under the CRAMS and CDMO models
The zero-observation outcome reflects the company's robust quality management systems and commitment to excellence in its operations.
The €70 million investment will allow the large-scale manufacturing of high-purity reagents for quality control and testing for biopharma customers, increasing annual output by several thousand tons
Exothera will manufacture Meissa’s MV-012-968 vaccine candidate under CGMP regulations to supply Phase 2 clinical trials
Under the terms of the collaboration, Vertex and Lonza will partner in the process development and scale-up for the manufacturing of the product portfolio and co-invest to build a dedicated new facility in Portsmouth, New Hampshire (US)
Subscribe To Our Newsletter & Stay Updated
